Watch as Resolution’s senior leadership team, joined by leading hepatologists Professor Jonathan Fallowfield and Dr Elliot Tapper, in Resolution’s second annual R&D webinar. This discussion was hosted live on Wednesday 17th September 2025 at 14:00 BST.

 

Access the full webinar replay here.

 

Webinar agenda:

  1. 1. Opening remarks, by Dr Amir Hefni, Chief Executive Officer at Resolution Therapeutics
  2. 2.The clinical unmet need in decompensated cirrhosis, by Dr Elliot Tapper, Andrews Family Research Professor of Hepatology and Associate Professor of Internal Medicine at the University of Michigan Medical School
  3. 3. Why regenerative macrophage therapy for end-stage liver disease, by Professor Jonathan Fallowfield, Chief Investigator, Chair of Translational Liver Research and Principal Investigator at the University of Edinburgh
  4. 4. The voice of patients – tesimonials from MATCH participants treated with non-engineered macrophages
  5. 5. Regenerative Macrophage Therapy science, by Dr Lara Campana, SVP Research & Translational Science at Resolution Therapeutics
  6. 6. RTX001 Clinical Programme,  by Dr Cliff Brass, Chief Medical Officer at Resolution Therapeutics
  7. 7. Q&A, led by Dr Amir Hefni